RG-1530   Click here for help

GtoPdb Ligand ID: 10361

Synonyms: compound 2 [PMID: 24900658] | R-1530 | R1530 | RG1530
Compound class: Synthetic organic
Comment: RG-1530 is an orally active multikinase inhibitor, with a high affinity for polo like kinase 4 (PLK4). Its PLK4 inhibitory action was expoited for antiproliferative potential [1-4]. PLK4 is expressed at very low levels in normal cells, but its expression can be upregulated in cancer cells where it localises to the centriole and is essential for controlling centriole duplication and mitotic progression. This makes PLK4 an ideal target for disrupting mitosis in cancer cells.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 2
Hydrogen bond donors 2
Rotatable bonds 2
Topological polar surface area 66.59
Molecular weight 356.08
XLogP 5.83
No. Lipinski's rules broken 1
Click here for help
Canonical SMILES COc1cc2[nH]c3n[nH]c(c3nc(c2cc1F)c1ccccc1Cl)C
Isomeric SMILES COc1cc2[nH]c3n[nH]c(c3nc(c2cc1F)c1ccccc1Cl)C
InChI InChI=1S/C18H14ClFN4O/c1-9-16-18(24-23-9)21-14-8-15(25-2)13(20)7-11(14)17(22-16)10-5-3-4-6-12(10)19/h3-8H,1-2H3,(H2,21,23,24)
No information available.
Summary of Clinical Use Click here for help
A single Phase 1 study of RG-1530 in patients with advanced solid tumours has been completed (NCT00493155), and these is no evidence of further/ongoing development.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT00493155 A Multiple Ascending Dose Study of R1530 in Patients With Advanced Solid Tumors. Phase 1 Interventional Hoffmann-La Roche